FDA
-
-
-
-
-
-
-
Spark Therapeutics (ONCE) Plans Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at WORLDSymposium
-
-
-
-
-
-
-
European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
-
-
-
-
-
-
-
Spark Therapeutics (ONCE) Delivers Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA (voretigene neparvovec-rzyl)
-
-
-
-
-
-
-
Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
-
-
-
-
-
-
-
Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
-
-
-
-
-
-
-
uniQure (QURE), Others Gains Following Gottlieb Comments on Gene Therapy
-
-
-
-
-
-
-
Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

